
-
Protalix Biotherapeutics NYSE American:PLX Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.
Location: 2 University Plaza, Hackensack, NJ, 07601, United States | Website: https://www.protalix.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
97.07M
Cash
34.74M
Avg Qtr Burn
-143K
Short % of Float
1.61%
Insider Ownership
10.39%
Institutional Own.
10.77%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ELFABRIO (Pegunigalsidase alfa )(PRX-102) Details Genetic disorder, Rare genetic disease | Approved Update | |
Elelyso® (taliglucerase alpha) Details Genetic disorder, Rare genetic disease | Approved Quarterly sales | |
PRX-115 Details Chronic refractory gout | Phase 2 Initiation | |
Alidornase alfa (PRX-110) Details Genetic disorder, Rare genetic disease, Cystic fibrosis | Failed Discontinued | |
OPRX-106 Details Inflammatory disease, Bowel disorder | Failed Discontinued |